Abbott Sees Absorb Bioresorbable Implant As Stent Market Game Changer
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm announced CE mark clearance Jan. 10, making Absorb the first drug-eluting bioresorbable vascular scaffold available to treat coronary artery disease. Abbott expects to submit a PMA by 2015.
You may also be interested in...
News In Brief
HeartWare HVAD submission
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.